A Post-Marketing Study to Further Assess the Immunogenicity and Safety of Unituxin in High-Risk Neuroblastoma Patients
Phase of Trial: Phase IV
Latest Information Update: 09 Feb 2017
At a glance
- Drugs Dinutuximab (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- Sponsors United Therapeutics Corporation
- 03 Feb 2017 Status changed from recruiting to discontinued.
- 12 Jul 2016 Status changed from not yet recruiting to recruiting.
- 01 Mar 2016 New trial record